Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry

Roberto Caporali, Piercarlo Sarzi-Puttini, Fabiola Atzeni, Roberto Gorla, Matteo Filippini, Antonio Marchesoni, Ennio Giulio Favalli, Francesca Bobbio-Pallavicini, Carlomaurizio Montecucco

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.

Original languageEnglish
Pages (from-to)465-469
Number of pages5
JournalAutoimmunity Reviews
Volume9
Issue number6
DOIs
Publication statusPublished - Apr 2010

Fingerprint

Registries
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Antirheumatic Agents
Therapeutics
Biological Factors
Pharmaceutical Preparations

Keywords

  • Anti-TNF-alpha
  • DMARDs
  • Methotrexate
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Switching TNF-alpha antagonists in rheumatoid arthritis : The experience of the LORHEN registry. / Caporali, Roberto; Sarzi-Puttini, Piercarlo; Atzeni, Fabiola; Gorla, Roberto; Filippini, Matteo; Marchesoni, Antonio; Favalli, Ennio Giulio; Bobbio-Pallavicini, Francesca; Montecucco, Carlomaurizio.

In: Autoimmunity Reviews, Vol. 9, No. 6, 04.2010, p. 465-469.

Research output: Contribution to journalArticle

Caporali, Roberto ; Sarzi-Puttini, Piercarlo ; Atzeni, Fabiola ; Gorla, Roberto ; Filippini, Matteo ; Marchesoni, Antonio ; Favalli, Ennio Giulio ; Bobbio-Pallavicini, Francesca ; Montecucco, Carlomaurizio. / Switching TNF-alpha antagonists in rheumatoid arthritis : The experience of the LORHEN registry. In: Autoimmunity Reviews. 2010 ; Vol. 9, No. 6. pp. 465-469.
@article{678be8bef3f348ba999a473dc55aa399,
title = "Switching TNF-alpha antagonists in rheumatoid arthritis: The experience of the LORHEN registry",
abstract = "New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50{\%} of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.",
keywords = "Anti-TNF-alpha, DMARDs, Methotrexate, Rheumatoid arthritis",
author = "Roberto Caporali and Piercarlo Sarzi-Puttini and Fabiola Atzeni and Roberto Gorla and Matteo Filippini and Antonio Marchesoni and Favalli, {Ennio Giulio} and Francesca Bobbio-Pallavicini and Carlomaurizio Montecucco",
year = "2010",
month = "4",
doi = "10.1016/j.autrev.2009.12.010",
language = "English",
volume = "9",
pages = "465--469",
journal = "Autoimmunity Reviews",
issn = "1568-9972",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Switching TNF-alpha antagonists in rheumatoid arthritis

T2 - The experience of the LORHEN registry

AU - Caporali, Roberto

AU - Sarzi-Puttini, Piercarlo

AU - Atzeni, Fabiola

AU - Gorla, Roberto

AU - Filippini, Matteo

AU - Marchesoni, Antonio

AU - Favalli, Ennio Giulio

AU - Bobbio-Pallavicini, Francesca

AU - Montecucco, Carlomaurizio

PY - 2010/4

Y1 - 2010/4

N2 - New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.

AB - New biologic agents have changed the paradigm of rheumatoid arthritis treatment, leading to improvement in managing patients' refractory to classical DMARDs. Anti-TNF-alpha is used as first-line treatment in patients failing to respond to classical DMARDs. However, up to 50% of patients fail to respond to these drugs or develop adverse events leading to treatment discontinuation: in these cases the optimal treatment strategy is still a matter of debate even if trying with a second anti-TNF-alpha is considered a good option. We report data of patients switching from a first to a second anti-TNF-alpha from an Italian registry of patients with rheumatoid arthritis, showing that switching is valuable in patients stopping a first anti-TNFα drug. The patients with higher disease activity levels and those stopping the first anti-TNFα treatment because of a lack of efficacy are very likely to respond to the second treatment.

KW - Anti-TNF-alpha

KW - DMARDs

KW - Methotrexate

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=77950300568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950300568&partnerID=8YFLogxK

U2 - 10.1016/j.autrev.2009.12.010

DO - 10.1016/j.autrev.2009.12.010

M3 - Article

C2 - 20044040

AN - SCOPUS:77950300568

VL - 9

SP - 465

EP - 469

JO - Autoimmunity Reviews

JF - Autoimmunity Reviews

SN - 1568-9972

IS - 6

ER -